Research Analysts’ Recent Ratings Changes for West Pharmaceutical Services (WST)

Several analysts have recently updated their ratings and price targets for West Pharmaceutical Services (NYSE: WST):

• 11/2/2026 – West Pharmaceutical Services was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 11/2/2026 – West Pharmaceutical Services had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $475.00 price target on the stock.
• 11/1/2026 – West Pharmaceutical Services was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/30/2026 – West Pharmaceutical Services had its price target raised by Citigroup from $412.00 to $494.00. They now have a “buy” rating on the stock.
• 10/30/2026 – West Pharmaceutical Services had its price target raised by TD Cowen from $420.00 to $500.00. They now have a “buy” rating on the stock.
• 10/30/2026 – West Pharmaceutical Services had its price target raised by Barclays from $440.00 to $500.00. They now have an “overweight” rating on the stock.
• 10/24/2026 – West Pharmaceutical Services was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/13/2026 – West Pharmaceutical Services had its price target raised by TD Cowen from $410.00 to $420.00. They now have a “buy” rating on the stock.
• 10/7/2026 – West Pharmaceutical Services had its price target raised by Barclays from $400.00 to $440.00. They now have an “overweight” rating on the stock.
• 9/22/2026 – West Pharmaceutical Services was upgraded by Morgan Stanley from “equal weight” to “overweight”. They now have a $400.00 price target on the stock, up from $365.00.
• 9/9/2026 – West Pharmaceutical Services had its price target raised by UBS Group from $340.00 to $415.00. They now have a “buy” rating on the stock.

West Pharmaceutical Services Price Performance

NYSE:WST traded up $1.80 during mid-day trading on Wednesday, hitting $408.79. 43,220 shares of the company’s stock traded hands, compared to its average volume of 809,683. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.10 and a current ratio of 2.82. The firm’s 50 day simple moving average is $369.96 and its 200 day simple moving average is $314.55. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $438.27. The company has a market cap of $28.48 billion, a PE ratio of 45.88, a price-to-earnings-growth ratio of 2.48 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.20 by $0.46. The company had revenue of $874.50 million during the quarter, compared to analysts’ expectations of $827.12 million. West Pharmaceutical Services had a net margin of 18.81% and a return on equity of 21.78%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.96 earnings per share. Sell-side analysts expect that West Pharmaceutical Services, Inc. will post 9.46 EPS for the current year.

West Pharmaceutical Services Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 18th. Investors of record on Wednesday, November 11th will be given a dividend of $0.26 per share. The ex-dividend date is Tuesday, November 10th. This represents a $1.04 annualized dividend and a dividend yield of 0.3%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.22. West Pharmaceutical Services’s payout ratio is presently 9.88%.

Insider Transactions at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Annette Favorite sold 2,524 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $365.00, for a total transaction of $921,260.00. Following the sale, the vice president owned 21,818 shares in the company, valued at approximately $7,963,570. This represents a 10.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 15,659 shares of company stock valued at $5,443,749. 0.60% of the stock is currently owned by corporate insiders.

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.